These may include injection site reactions such as redness, swelling, or tenderness that resolve within 24 to 48 hours
Response: We acknowledge the commenter's recommendation for earlier removal of the measure but note that the proposed adoption of the Emergency Care Access & Timeliness eCQM begins with voluntary reporting for the CY 2027 reporting period, followed by mandatory reporting beginning with the CY 2028 reporting period/CY 2030 payment determination
Reduced absorption of the B12-intrinsic factor complex can be caused by various gastrointestinal conditions including Crohns disease, celiac disease, intestinal bacterial overgrowth and intestinal parasites
We received the application for a new device category for transitional pass-through payment status for the LithoVue TM Elite System on March 3, 2025, which is within 3 years of the date of the initial FDA marketing authorization
Is the reconstitution process different for compounded tirzepatide vs research-grade
The optimal frequency and dosage varies person to person
